$GALT
GALECTIN THERAPEUTICS INC

2014 Q1 Form 10-K Financial Statement

#000119312514110529 Filed on March 21, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2013 2012 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.070M $6.420M $1.380M
YoY Change 41.78% 19.55% -45.02%
% of Gross Profit
Research & Development $2.772M $5.688M $1.000M
YoY Change 58.22% 25.65% 16.28%
% of Gross Profit
Depreciation & Amortization $2.000K $12.00K $0.00
YoY Change -33.33% 33.33%
% of Gross Profit
Operating Expenses $4.844M $12.10M $2.380M
YoY Change 51.0% 22.27% -29.38%
Operating Profit -$4.844M -$12.10M
YoY Change 51.0% 22.27%
Interest Expense -$270.0K $20.00K $10.00K
YoY Change -2800.0% 0.0%
% of Operating Profit
Other Income/Expense, Net -$266.0K $16.00K $0.00
YoY Change -5420.0% -92.86%
Pretax Income -$5.110M -$12.09M -$2.380M
YoY Change 59.69% 24.9% -29.38%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.110M -$12.09M -$2.380M
YoY Change 59.54% 24.94% -29.38%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$252.1K -$716.7K -$148.9K
COMMON SHARES
Basic Shares Outstanding 21.93M shares 15.97M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q1 2013 2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $36.59M $10.49M $9.360M
YoY Change 421.23% 12.07% 46.25%
Cash & Equivalents $36.59M $10.49M $9.364M
Short-Term Investments
Other Short-Term Assets $150.0K $200.0K $150.0K
YoY Change 7.14% 33.33% 50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $36.75M $10.69M $9.517M
YoY Change 413.56% 12.29% 46.39%
LONG-TERM ASSETS
Property, Plant & Equipment $3.000K $0.00 $8.000K
YoY Change -57.14% -100.0% 33.33%
Goodwill
YoY Change
Intangibles $21.00K $30.00K
YoY Change -25.0% -16.67%
Long-Term Investments $130.0K
YoY Change
Other Assets $0.00 $6.000K
YoY Change -100.0% -91.43%
Total Long-Term Assets $154.0K $20.00K $44.00K
YoY Change 275.61% -50.0% -60.36%
TOTAL ASSETS
Total Short-Term Assets $36.75M $10.69M $9.517M
Total Long-Term Assets $154.0K $20.00K $44.00K
Total Assets $36.90M $10.71M $9.561M
YoY Change 412.77% 12.03% 44.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $486.0K $760.0K $397.0K
YoY Change 53.8% 90.0% 3.39%
Accrued Expenses $1.451M $1.650M $1.161M
YoY Change 25.95% 42.24% -25.15%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.937M $2.490M $1.638M
YoY Change 31.95% 51.83% -26.05%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $6.000K
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00 $6.000K
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.937M $2.490M $1.638M
Total Long-Term Liabilities $0.00 $0.00 $6.000K
Total Liabilities $1.937M $2.490M $1.644M
YoY Change 31.5% 51.83% -25.78%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $22.00K $16.00K
YoY Change 37.5% 23.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $28.27M $8.230M $1.165M
YoY Change
Total Liabilities & Shareholders Equity $36.90M $10.71M $9.561M
YoY Change 412.77% 12.03% 44.6%

Cashflow Statement

Concept 2014 Q1 2013 2012 Q4
OPERATING ACTIVITIES
Net Income -$5.110M -$12.09M -$2.380M
YoY Change 59.54% 24.94% -29.38%
Depreciation, Depletion And Amortization $2.000K $12.00K $0.00
YoY Change -33.33% 33.33%
Cash From Operating Activities -$3.619M -$7.484M -$1.750M
YoY Change 49.36% -0.21% 12.9%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$10.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$400.0K $60.00K
YoY Change
Cash From Investing Activities -$400.0K $0.00 $50.00K
YoY Change -100.0% -600.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $28.18M $3.833M
YoY Change -63.15%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 30.12M 8.609M 0.000
YoY Change 39022.08% -17.25%
NET CHANGE
Cash From Operating Activities -3.619M -7.484M -1.750M
Cash From Investing Activities -400.0K 0.000 50.00K
Cash From Financing Activities 30.12M 8.609M 0.000
Net Change In Cash 26.11M 1.125M -1.700M
YoY Change -1212.75% -62.08% 8.97%
FREE CASH FLOW
Cash From Operating Activities -$3.619M -$7.484M -$1.750M
Capital Expenditures $0.00 $0.00 -$10.00K
Free Cash Flow -$3.619M -$7.484M -$1.740M
YoY Change 49.36% -0.28% 12.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2003Q1 us-gaap Share Price
SharePrice
6.00
CY2003Q1 galt Common Stock Additional Shares Issued
CommonStockAdditionalSharesIssued
2042 shares
CY2008Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
9.00
CY2008Q1 us-gaap Share Price
SharePrice
3.54
CY2008Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
984000
CY2008Q1 us-gaap Share Price
SharePrice
2.40
CY2003Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
261000
CY2008Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
3.00
CY2008Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2281000
CY2009Q1 galt Minimum Company Market Capitalization
MinimumCompanyMarketCapitalization
100000000
CY2009Q1 galt Accrued Separation Agreement
AccruedSeparationAgreement
1000000
CY2012Q1 galt Warrant Expiration Date
WarrantExpirationDate
2016-05-02
CY2014Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21932775 shares
CY2003Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
32.40
CY2003Q2 galt Purchase Price Per Unit Under Private Placement
PurchasePricePerUnitUnderPrivatePlacement
12.00
CY2008Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
6.00
CY2008Q3 galt Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P3Y
CY2011Q3 galt Operating Leases Monthly Base Rent Expense
OperatingLeasesMonthlyBaseRentExpense
235000
CY2013Q3 galt Minimum Company Market Capitalization
MinimumCompanyMarketCapitalization
100000000
CY2013Q3 galt Expected Future Payments
ExpectedFuturePayments
1000000
CY2001Q3 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
12.00
CY2001Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
39.00
CY2001Q3 us-gaap Share Price
SharePrice
13.68
CY2001Q3 us-gaap Convertible Debt
ConvertibleDebt
1126000
CY2001Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
503000
CY2002Q3 galt Purchase Price Per Unit Under Private Placement
PurchasePricePerUnitUnderPrivatePlacement
6.00
CY2012Q4 galt Operating Leases Annual Rent
OperatingLeasesAnnualRent
15000
CY2002Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
236000
CY2002Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
150000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0090 pure
CY2013Q2 dei Entity Public Float
EntityPublicFloat
55400000
CY2001Q4 us-gaap Share Price
SharePrice
13.68
CY2001Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
886000
CY2002Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
21.00
CY2002Q4 us-gaap Share Price
SharePrice
21.00
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1562500 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2002Q4 galt Common Stock Issuable Shares Issuable
CommonStockIssuableSharesIssuable
29042 shares
CY2002Q4 galt Common Stock Warrants Term
CommonStockWarrantsTerm
P10Y
CY2008Q4 galt Exercise Price Of Warrants Expired Without Exercise
ExercisePriceOfWarrantsExpiredWithoutExercise
3.78
CY2008Q4 galt Warrants Expired Without Exercise
WarrantsExpiredWithoutExercise
500000 shares
CY2010Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
7.20
CY2010Q4 galt Warrant Liabilities Fair Value Disclosure
WarrantLiabilitiesFairValueDisclosure
861000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
6673405 shares
CY2011Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.15 pure
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.83
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3091474 shares
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
-2125000
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
200000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6397000
CY2011Q4 galt Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber
166668 shares
CY2011Q4 galt Class Of Warrant Or Right Intrinsic Value Of Warrants Or Rights
ClassOfWarrantOrRightIntrinsicValueOfWarrantsOrRights
1385
CY2011Q4 galt Bank Deposit
BankDeposit
59000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16060853 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
7424241 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1562500 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.66
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3539961 shares
CY2012Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1472051 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16060853 shares
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1638000
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
42000
CY2012Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
80000
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
66000
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
10000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
80535000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
397000
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
109000
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
24991000
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
1165000
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
632000
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1161000
CY2012Q4 us-gaap Liabilities
Liabilities
1644000
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
48000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
16000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9561000
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
21753000
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
24991000
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
6000
CY2012Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
30000
CY2012Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
74000
CY2012Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2921000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8000
CY2012Q4 us-gaap Assets
Assets
9561000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9364000
CY2012Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
80018000
CY2012Q4 us-gaap Security Deposit
SecurityDeposit
6000
CY2012Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
78000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
153000
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
317000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
9517000
CY2012Q4 galt Undesignated Capital Stock Shares Authorized But Unissued
UndesignatedCapitalStockSharesAuthorizedButUnissued
11999000 shares
CY2012Q4 galt Undesignated Capital Stock No Par Value
UndesignatedCapitalStockNoParValue
0.01
CY2012Q4 galt Undesignated Capital Stock Shares Outstanding
UndesignatedCapitalStockSharesOutstanding
8001000 shares
CY2012Q4 galt Accrued Separation Agreement
AccruedSeparationAgreement
1000000
CY2012Q4 galt Undesignated Capital Stock Shares Authorized
UndesignatedCapitalStockSharesAuthorized
20000000 shares
CY2012Q4 galt Undesignated Capital Stock Value
UndesignatedCapitalStockValue
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18386900 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
6035229 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1452500 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2084463 shares
CY2013Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
3348705 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.70
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3348705 shares
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1256735 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1452500 shares
CY2013Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
4.43
CY2013Q4 us-gaap Share Price
SharePrice
8.08
CY2013Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
4.70
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.43
CY2013Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
2084463 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6035229 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18386900 shares
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
64000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25881000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
30583000
CY2013Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
23000
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
74000
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
4302000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3000
CY2013Q4 us-gaap Assets
Assets
10713000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10489000
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
7721000
CY2013Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
101965000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
36000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2486000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
526000
CY2013Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
73000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
71000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
22000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
102841000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
762000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
103000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
30583000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
1481000
CY2013Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
1496000
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
587000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1651000
CY2013Q4 us-gaap Liabilities
Liabilities
2486000
CY2013Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
55000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
18000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10713000
CY2013Q4 us-gaap Security Deposit
SecurityDeposit
6000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11420000
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4522000
CY2013Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
78000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
198000
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
400000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
10687000
CY2013Q4 galt Undesignated Capital Stock No Par Value
UndesignatedCapitalStockNoParValue
0.01
CY2013Q4 galt Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1.00 pure
CY2013Q4 galt Undesignated Capital Stock Shares Outstanding
UndesignatedCapitalStockSharesOutstanding
8001000 shares
CY2013Q4 galt Number Of Compensation Plans
NumberOfCompensationPlans
3 CompensationPlan
CY2013Q4 galt Accrued Separation Agreement
AccruedSeparationAgreement
1000000
CY2003Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
18000
CY2013Q4 galt Undesignated Capital Stock Shares Authorized
UndesignatedCapitalStockSharesAuthorized
20000000 shares
CY2013Q4 galt Undesignated Capital Stock Value
UndesignatedCapitalStockValue
galt Warrant Expense
WarrantExpense
8763000
galt Number Of Warrants Exercise
NumberOfWarrantsExercise
5000000 Warrants
CY2008Q1 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.95 pure
CY2008Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0251 pure
CY2008Q1 galt Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
1400 shares
CY2008Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1250000 shares
CY2008Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1044000
CY2008Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
369000
CY2008Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3381000
CY2008Q1 galt Stock Issued Issuance Costs Warrants Issued For Agents Fair Value
StockIssuedIssuanceCostsWarrantsIssuedForAgentsFairValue
56000
CY2008Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
502000
CY2008Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
100000
CY2009Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1548000
CY2009Q1 galt Class Of Warrant Or Right Issuable
ClassOfWarrantOrRightIssuable
6000000 shares
CY2009Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
287000
CY2009Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
296000
CY2010Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
536000
CY2013Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
500000 shares
CY2013Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2013Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
3000000
CY2013Q3 galt Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
0 shares
CY2010Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
322000
CY2010Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
297000
CY2012Q1 galt Issuance Of Equity Warrants In Connection With Equity Offerings
IssuanceOfEquityWarrantsInConnectionWithEquityOfferings
143000
CY2012Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2666722 shares
CY2012Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
10403000
CY2012Q1 galt Units Issued During Period Units New Issues
UnitsIssuedDuringPeriodUnitsNewIssues
1333361 shares
CY2012Q1 galt Common Stock Warrants Issued
CommonStockWarrantsIssued
1333361 shares
CY2012Q1 galt Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
46378 shares
CY2012Q1 galt Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
5.63
CY2012Q1 galt Proceeds From Issuance Or Sale Of Equity Gross
ProceedsFromIssuanceOrSaleOfEquityGross
12000000
CY2012Q1 galt Issuance Of Equity Warrants In Connection With Equity Offerings
IssuanceOfEquityWarrantsInConnectionWithEquityOfferings
4445000
CY2012Q2 galt Organizational And Separation Related Charges
OrganizationalAndSeparationRelatedCharges
1000000
CY2013Q1 galt Milestone Payments
MilestonePayments
1000000
CY2008Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
20000
CY2008Q3 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
20000
CY2008Q3 galt Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
50000 shares
CY2009Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
473000
CY2009Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
305000
CY2012Q4 galt Lawsuit Damage Claim
LawsuitDamageClaim
1000000
CY2003Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
181334 shares
CY2011Q3 galt Lease Extension Period
LeaseExtensionPeriod
P1Y
CY2011Q3 galt Lease Agreement Expiration Date
LeaseAgreementExpirationDate
2012-09-30
CY2001Q3 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
99705 shares
CY2003Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1070000
CY2009Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
310000
CY2010Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
308000
CY2012Q1 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
3324 shares
CY2012Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1.6667 pure
CY2009Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
83334 shares
CY2009Q1 us-gaap Royalty Revenue
RoyaltyRevenue
50000000
CY2009Q1 galt Severance Payment Period
SeverancePaymentPeriod
P6M
CY2009Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
801000
CY2002Q3 galt Private Placement Number Of Units Announced
PrivatePlacementNumberOfUnitsAnnounced
1666667 shares
CY2010Q4 galt Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
500 shares
CY2003Q1 galt Offering Costs Payable
OfferingCostsPayable
18000
CY2003Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
399917 shares
CY2003Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
128000
CY2003Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
4671000
CY2003Q2 galt Private Placement Number Of Units Announced
PrivatePlacementNumberOfUnitsAnnounced
416667 shares
CY2003Q2 galt Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
18269 shares
CY2011Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
44000
CY2011Q3 galt Operating Lease Maturity Period
OperatingLeaseMaturityPeriod
P1Y
CY2001Q3 us-gaap Debt Conversion Converted Instrument Warrants Or Options Issued1
DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
93801 shares
CY2012Q4 galt Operating Lease Expiration Period
OperatingLeaseExpirationPeriod
P1Y
CY2001 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
114884 shares
CY2001 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
17000
CY2001 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
2221000
CY2002 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
537227 shares
CY2002 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
212000
CY2002 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
2861000
CY2002 galt Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
18334 shares
CY2010 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
489000
CY2010 us-gaap Proceeds From Grantors
ProceedsFromGrantors
255000
CY2011 us-gaap Proceeds From Grantors
ProceedsFromGrantors
234000
CY2011 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
524000
CY2011 galt Additional Share Based Compensation Expense Related To Modified Stock Options
AdditionalShareBasedCompensationExpenseRelatedToModifiedStockOptions
63000
CY2013 dei Trading Symbol
TradingSymbol
GALT
CY2013 dei Entity Registrant Name
EntityRegistrantName
GALECTIN THERAPEUTICS INC
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013 dei Amendment Flag
AmendmentFlag
false
CY2013 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013 dei Document Type
DocumentType
10-K
CY2013 dei Document Period End Date
DocumentPeriodEndDate
2013-12-31
CY2013 dei Entity Central Index Key
EntityCentralIndexKey
0001133416
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2013 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
14.19
CY2013 us-gaap Basis Of Accounting
BasisOfAccounting
<div> <table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left"><font style="font-family:Times New Roman" size="2"><b>1.</b></font></td> <td align="left" valign="top"><font style="font-family:Times New Roman" size="2"><b>Nature of Business and Basis of Presentation</b></font></td> </tr> </table> <p style="margin-top:6px;margin-bottom:0px; margin-left:4%"> <font style="font-family:Times New Roman" size="2">Galectin Therapeutics Inc. (the &#x201C;Company&#x201D;) is a development-stage company that is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. These candidates are based on the Company&#x2019;s targeting of galectin proteins which are key mediators of biologic and pathologic function. These compounds also may have application for drugs to treat other diseases and chronic health conditions.</font></p> <p style="margin-top:12px;margin-bottom:0px; margin-left:4%"> <font style="font-family:Times New Roman" size="2">On March&#xA0;23, 2012, the Company effected a one-for-six reverse stock split. All common share and per share amounts in these financial statements have been adjusted to reflect the effect of the reverse split.</font></p> <p style="margin-top:12px;margin-bottom:0px; margin-left:4%"> <font style="font-family:Times New Roman" size="2">The Company has operated at a loss since its inception and has had no revenues. The Company anticipates that losses will continue for the foreseeable future. At December&#xA0;31, 2013, the Company had $10,489,000 of unrestricted cash and cash equivalents available to fund future operations. Additionally, in January and February 2014, the Company received $28,178,000 in net proceeds from the issuance of common stock at market through its at the market (&#x201C;ATM&#x201D;) financing arrangement and $1,500,000 from the exercise of stock purchase warrants.</font></p> <p style="margin-top:12px;margin-bottom:0px; margin-left:4%"> <font style="font-family:Times New Roman" size="2">As shown in the consolidated financial statements, the Company incurred cumulative net losses applicable to common stockholders of $102.2 million for the period from inception (July 10, 2000) through December&#xA0;31, 2013. The Company&#x2019;s net losses have resulted principally from costs associated with (i)&#xA0;research and development expenses, including clinical trial costs, (ii)&#xA0;general and administrative activities and (iii)&#xA0;the Company&#x2019;s financing transactions including interest, dividend payments, and the costs related to fair value accounting for the Company&#x2019;s convertible debt instruments. As a result of planned expenditures for future research, discovery, development and commercialization activities and potential legal cost to protect its intellectual property, the Company expects to incur additional losses and use additional cash in its operations for the foreseeable future. Through December&#xA0;31, 2013, the Company had raised a net total of $77.4 million in capital through sale and issuance of common stock, common stock purchase warrants, convertible preferred stock and debt securities in public and private offerings. From inception (July 10, 2000) through December&#xA0;31, 2013, the Company used cash of $66.0 million in its operations.</font></p> <p style="margin-top:12px;margin-bottom:0px; margin-left:4%"> <font style="font-family:Times New Roman" size="2">The Company was founded in July 2000, was incorporated in the State of Nevada in January 2001 under the name &#x201C;Pro-Pharmaceuticals, Inc.,&#x201D; and changed its name to &#x201C;Galectin Therapeutics Inc.&#x201D; on May&#xA0;26, 2011.&#xA0;On&#xA0;March&#xA0;23, 2012, the Company began trading on The NASDAQ Capital Market under the symbol GALT. Prior to March&#xA0;23, 2012, the Company was traded on the Over-the Counter Bulletin Board (&#x201C;OTCBB&#x201D;) under the symbol GALT.OB (previously PRWP.OB) from January&#xA0;21, 2009 to March&#xA0;22, 2012 after the Company was delisted from the NYSE Alternext US (&#x201C;Exchange&#x201D;), formerly the American Stock Exchange, due to non-compliance with the Exchange minimum shareholders&#x2019; equity requirements on January&#xA0;9, 2009.</font></p> <p style="margin-top:12px;margin-bottom:0px; margin-left:4%"> <font style="font-family:Times New Roman" size="2">The Company is subject to a number of risks similar to those of other development-stage companies, including dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with clinical trials of products, dependence on third-party collaborators for research operations, need for regulatory approval of products, risks associated with protection of intellectual property, and competition with larger, better-capitalized companies. Successful completion of the Company&#x2019;s development program and, ultimately, the attainment of profitable operations is dependent upon future events, including obtaining adequate financing to fulfill its development activities and achieving a level of revenues adequate to support the Company&#x2019;s cost structure. There are no assurances that the Company will be able to obtain additional financing on favorable terms, or at all, or successfully market its products.</font></p> </div>
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0117 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.15 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.17
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.34 pure
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.89
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.018 pure
CY2013 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P5Y
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y3M15D
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.366 pure
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16874000 shares
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7484000
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
213008 shares
CY2013 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:0px;margin-bottom:0px; margin-left:4%"> <font style="font-family:Times New Roman" size="2"><i>Concentration of Credit Risk.</i>&#xA0;&#xA0;&#xA0;&#xA0;Financial instruments that subject the Company to credit risk consist of cash and cash equivalents and certificates of deposit. The Company maintains cash and cash equivalents and certificates of deposit with well-capitalized financial institutions. At times, those amounts may exceed federally insured limits. The Company has no significant concentrations of credit risk.</font></p> </div>
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.053 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
403674 shares
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11952705 shares
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.30
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.18
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
1344012 shares
CY2013 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:12px;margin-bottom:0px; margin-left:4%"> <font style="font-family:Times New Roman" size="2"><i>Use of Estimates.</i>&#xA0;&#xA0;&#xA0;&#xA0;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that may affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities. Management&#x2019;s estimates and judgments include assumptions used in stock option and warrant liability valuations, useful lives of property and equipment and intangible assets, accrued liabilities, deferred income taxes and various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.</font></p> </div>
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
425426 shares
CY2013 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
81591 shares
CY2013 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P4Y6M
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.000 pure
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M5D
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
5000 shares
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
614041 shares
CY2013 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P6Y10M17D
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3833000
CY2013 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
-8763000
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
271000
CY2013 us-gaap Investment Income Interest
InvestmentIncomeInterest
16000
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2406000
CY2013 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21947000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
39000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-12104000
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
16000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-12088000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3789000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6416000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8609000
CY2013 us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
707000
CY2013 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
54000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
3789000
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1125000
CY2013 us-gaap Operating Expenses
OperatingExpenses
12104000
CY2013 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
867000
CY2013 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1500000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1498000
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3833000
CY2013 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-6000
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
271000
CY2013 galt Supplemental Dividends On Convertible Preferred Stock
SupplementalDividendsOnConvertiblePreferredStock
867000
CY2013 galt Proceeds From Stock Option And Warrant Exercises
ProceedsFromStockOptionAndWarrantExercises
4776000
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12000
CY2013 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
7000
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
36000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5688000
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
848000
CY2013 us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
229000
CY2013 galt Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod
50000 shares
CY2013 galt Stock Issuance Costs
StockIssuanceCosts
111000
CY2013 galt Stock Issued During Period Shares Stock Options Exercised Amount
StockIssuedDuringPeriodSharesStockOptionsExercisedAmount
378000
CY2013 galt Accretion Of Redeemable Convertible Preferred Stock
AccretionOfRedeemableConvertiblePreferredStock
175000
CY2013 galt Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.009 pure
CY2013 galt Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
4505000
CY2013 galt Adjustment For Modification Of Warrants
AdjustmentForModificationOfWarrants
8763000
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.93
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.16 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.34 pure
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.13
CY2012 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.033 pure
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M22D
CY2012 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.348 pure
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15131000 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.77
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7500000
CY2012 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
51830 shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.053 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
299683 shares
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13591312 shares
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.31
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
800000 shares
CY2012 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
51830 shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.002 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
616726 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
1379739 shares
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
595420 shares
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5000
CY2012 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-69000
CY2012 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
200000
CY2012 us-gaap Investment Income Interest
InvestmentIncomeInterest
24000
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2447000
CY2012 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10881000
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
55000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-9899000
CY2012 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
224000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-9675000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2766000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5372000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10403000
CY2012 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
56000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
2792000
CY2012 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2967000
CY2012 us-gaap Operating Expenses
OperatingExpenses
9899000
CY2012 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
976000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4527000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
162000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
404000
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10403000
CY2012 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
6000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.19 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y2M9D
CY2012 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-577000
CY2012 us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
230000
CY2012 galt Additional Share Based Compensation Expense Related To Modified Stock Options
AdditionalShareBasedCompensationExpenseRelatedToModifiedStockOptions
271000
CY2012 galt Issuance Of Common Stock And Warrants Value
IssuanceOfCommonStockAndWarrantsValue
10403000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-66037000
CY2012 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6000
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
216000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
1641000
CY2012 galt Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod
12177 shares
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
77400000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
431000
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
12243000
CY2012 galt Stock Issuance Costs
StockIssuanceCosts
1597000
CY2012 galt Stock Issued During Period Shares Stock Options Exercised Amount
StockIssuedDuringPeriodSharesStockOptionsExercisedAmount
96000
CY2012 galt Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.014 pure
CY2012 galt Conversion Of Accrued Liabilities To Common Stock
ConversionOfAccruedLiabilitiesToCommonStock
26000
CY2012 galt Issuance Of Equity Warrants In Connection With Equity Offerings
IssuanceOfEquityWarrantsInConnectionWithEquityOfferings
4445000
CY2012 galt Supplemental Dividends On Convertible Preferred Stock
SupplementalDividendsOnConvertiblePreferredStock
976000
CY2012 galt Reversal Of Sharebased Compensation
ReversalOfSharebasedCompensation
100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0168 pure
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
691000
us-gaap Investment Income Interest
InvestmentIncomeInterest
834000
us-gaap Stock Issued1
StockIssued1
107000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
15473000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-102221000
us-gaap Interest Paid
InterestPaid
114000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
53000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
195000
us-gaap Operating Income Loss
OperatingIncomeLoss
-86750000
us-gaap Subscription Revenue
SubscriptionRevenue
150000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2670000
us-gaap Net Income Loss
NetIncomeLoss
-84080000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
171000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15424000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
9000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
53452000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
77361000
us-gaap Paid In Kind Interest
PaidInKindInterest
4279000
us-gaap Share Based Compensation
ShareBasedCompensation
16163000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
10489000
us-gaap Operating Expenses
OperatingExpenses
86750000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
5104000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
10621000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
351000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3222000
us-gaap Interest Expense
InterestExpense
4451000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-835000
galt Reclassification Of Warrants To Liability
ReclassificationOfWarrantsToLiability
3193000
galt Stock Issued During Period Value Merger
StockIssuedDuringPeriodValueMerger
107000
galt Stock Issued During Period Value Conversion Or Exchange Of Convertible Securities
StockIssuedDuringPeriodValueConversionOrExchangeOfConvertibleSecurities
1036000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33298000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2474000
galt Stock Issuance Costs
StockIssuanceCosts
17000
galt Stock Issued During Period Value Founders
StockIssuedDuringPeriodValueFounders
9000
galt Value Of Beneficial Conversion Feature Of Preferred Stock
ValueOfBeneficialConversionFeatureOfPreferredStock
222000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
42926000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
567000
galt Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
18812000
galt Conversion Of Accrued Liabilities To Common Stock
ConversionOfAccruedLiabilitiesToCommonStock
329000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-9022000
us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
4274000
galt Cumulative Effect Of Initial Adoption Of New Accounting Principle Gross
CumulativeEffectOfInitialAdoptionOfNewAccountingPrincipleGross
-204000
galt Stock Based Compensation
StockBasedCompensation
157000
galt Adjustments To Additional Paid In Capital Deferred Compensation
AdjustmentsToAdditionalPaidInCapitalDeferredCompensation
-455000
galt Issuance Of Common Stock And Warrants Value
IssuanceOfCommonStockAndWarrantsValue
2221000
galt Issuance Of Equity Warrants In Connection With Equity Offerings
IssuanceOfEquityWarrantsInConnectionWithEquityOfferings
9482000
galt Supplemental Dividends On Convertible Preferred Stock
SupplementalDividendsOnConvertiblePreferredStock
5022000
galt Proceeds From Stock Option And Warrant Exercises
ProceedsFromStockOptionAndWarrantExercises
16069000
galt Issuance Of Warrants To Induce Conversion Of Notes Payable
IssuanceOfWarrantsToInduceConversionOfNotesPayable
503000
galt Unrealized Gain Loss In Debt Instrument Fair Value
UnrealizedGainLossInDebtInstrumentFairValue
-3426000
galt Adjustment For Modification Of Warrants
AdjustmentForModificationOfWarrants
8763000
CY2008Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2160000
CY2008Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
356000
CY2013Q2 galt Warrant Expense
WarrantExpense
8763000
CY2013Q2 galt Number Of Warrants Exercise
NumberOfWarrantsExercise
5000000 Warrants

Files In Submission

Name View Source Status
0001193125-14-110529-index-headers.html Edgar Link pending
0001193125-14-110529-index.html Edgar Link pending
0001193125-14-110529.txt Edgar Link pending
0001193125-14-110529-xbrl.zip Edgar Link pending
d630211d10k.htm Edgar Link pending
d630211dex211.htm Edgar Link pending
d630211dex231.htm Edgar Link pending
d630211dex311.htm Edgar Link pending
d630211dex312.htm Edgar Link pending
d630211dex321.htm Edgar Link pending
d630211dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
galt-20131231.xml Edgar Link completed
galt-20131231.xsd Edgar Link pending
galt-20131231_cal.xml Edgar Link unprocessable
galt-20131231_def.xml Edgar Link unprocessable
galt-20131231_lab.xml Edgar Link unprocessable
galt-20131231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending